- Home
- Applications
Multispecific antibodies have emerged as indispensable assets in the realms of biomedical exploration and therapy. Their extraordinary capability to engage with multiple antigens renders them invaluable across a spectrum of applications. Leveraging the innovative ImmuBridge™ platform, our company engineers multispecific antibodies renowned for their exceptional affinity and precise target specificity. These antibodies not only serve as pivotal components in biomedical investigations but also hold promise for adaptation into diagnostic tools and therapeutic agents, propelling the frontier of medical progress.
In the realm of therapeutic development, the utilization of multispecific antibodies has emerged as a transformative strategy, enhancing the precision and efficacy of targeted drug delivery systems and cancer immunotherapy.
Multispecific antibodies have the ability to precisely deliver therapeutic agents to specific cells or tissues. This targeted approach minimizes off-target effects and enhances the safety of therapies. Using multispecific antibodies in developing targeted drug delivery systems offers various advantages.
Multispecific antibodies have become pivotal in the realm of cancer immunotherapy, providing innovative approaches to target and stimulate the immune system in the fight against cancer cells. These antibodies are designed to simultaneously target cancer cells and immune cells, facilitating precise interactions between the immune system and tumor cells.
Table. 1 Cancer immunotherapy applications of multispecific antibodies and corresponding targets.
| Cancer Types | Targets |
| Breast Cancer | Human Epidermal Growth Factor Receptor 2 (HER2), Epidermal Growth Factor Receptor (EGFR) |
| Colorectal Cancer | EGFR, Carcinoembryonic Antigen (CEA) |
| Melanoma | Programmed Cell Death Protein 1 (PD-1), Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) |
| Lung Cancer | Programmed Death-Ligand 1 (PD-L1), EGFR |
| Lymphoma | Cluster of Differentiation 20 (CD20), CD19 |
| Ovarian Cancer | Cancer Antigen 125 (CA-125), Folate Receptor Alpha |
| Prostate Cancer | Prostate-Specific Membrane Antigen (PSMA), Prostate Stem Cell Antigen (PSCA) |
| Pancreatic Cancer | CEA, Mucin 1 (MUC1) |
| Leukemia | CD19, CD22 |
| Glioblastoma | Epidermal Growth Factor Receptor Variant III (EGFRvIII), Interleukin-13 Receptor Alpha 2 (IL-13Rα2) |
| Renal Cell Carcinoma | Carbonic Anhydrase IX (CA-IX), PD-L1 |
| Bladder Cancer | PD-L1, Nectin-4 |
Moreover, utilizing its multiple antigen-binding domains, multispecific antibodies can target various immune cell regulatory mechanisms to activate potent immune responses, overcome cancer cell immune evasion, and achieve efficient and precise therapeutics.
Table. 2 Immune cell types targeted by multispecific antibodies and their corresponding targets.
| Immune Cell Types | Targets | ||
| T Cells |
|
|
|
| NK Cells |
|
|
|
Multispecific antibodies have the potential to enhance the specificity and sensitivity of diagnostic tests due to their ability to bind to multiple targets simultaneously. In diagnostic applications, multispecific antibodies can be engineered to detect various biomarkers, pathogens, or other specific molecules with higher accuracy, enabling more precise and efficient diagnostic assays.
Multispecific antibodies play a critical role in immunoassay development, enhancing the sensitivity and specificity of detecting disease biomarkers. By targeting multiple epitopes simultaneously, these antibodies can amplify detection signals, enabling precise quantification of biomarkers in samples.
Immunoassay Development
Multispecific antibodies aid in the rapid and accurate detection of target analytes, crucial for point-of-care testing (POCT). By integrating multispecific antibodies into POCT, portable and user-friendly diagnostic tools can be developed for infectious disease screening, cardiac and tumor biomarker detection.
POCT Development
Multispecific antibodies facilitate the development of targeted imaging agents to precisely visualize disease biomarkers and tissues in diagnostic imaging. This targeted imaging approach enhances diagnostic accuracy and supports the formulation of personalized therapeutic strategies for affected individuals.
Imaging Agent Development
Our ImmuBridge™ multispecific antibody platform stands as a pioneering breakthrough in the industry, poised to transform the landscape of oncology and immunotherapy. Leveraging the state-of-the-art technology within this platform, our researchers excel in crafting next-generation T cell engagers (TCEs), such as BiTE antibodies and trispecific antibodies, to precisely target tumor antigens and achieve effective immunotherapy.
We are actively seeking partnerships to license our multispecific antibody platform or collaborate on the co-development of multispecific antibody drug candidates. Please feel free to contact us to discuss potential collaboration opportunities.
Reference
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Our ImmuBridge™️ platform is specifically designed for developing multispecific antibodies targeting tumor antigens. We provide comprehensive research services for cancer immunotherapy to drive advancements in the field.